Telehealth Prescribing Across State Lines: The 2026 Rules

Telehealth has opened the door to remote prescribing, but it has not dissolved state lines. In 2026, a physician treating a patient via video must still be licensed in the state where that patient is sitting — full stop. This guide walks through the in-state licensure rule, the Interstate Medical Licensure Compact, telehealth-specific registration frameworks, the post-COVID controlled-substance landscape under the 2024 DEA final rules, and how a multi-state physician network inside a compliant PC-MSO structure solves the coverage puzzle for wellness and medical aesthetics businesses operating nationally.

The foundational rule: prescribe where the patient is located

Every state medical practice act defines jurisdiction by the patient's location, not the prescriber's location. When a physician licensed only in California conducts a video visit with a patient physically in Texas, the physician is practicing medicine in Texas — without a Texas license. That is unlicensed practice regardless of the technology used.

This rule predates telehealth and is enforced uniformly. State medical boards have issued discipline for exactly this pattern, and the consequences include license suspension, civil penalties, and — for controlled substances — potential DEA action. The technology platform used is irrelevant; compliance begins with verifying the patient's location at the time of every encounter.

For businesses operating wellness, weight-management, hormone therapy, or aesthetics programs across multiple states, this creates a real operational challenge: every state in which patients reside requires at least one physician who holds an active, unrestricted license in that state. See our overview of medical director requirements by state for how licensure intersects with supervision ratios and scope-of-practice rules.

The Interstate Medical Licensure Compact (IMLC)

The Interstate Medical Licensure Compact is an agreement among member states that creates an expedited — not unified — licensure pathway. A physician who holds a "principal license" in one member state and meets qualifying criteria can submit a single application through the IMLC Commission to obtain individual licenses in additional member states.

Key facts for 2026:

• Participation: More than 40 states, the District of Columbia, and Guam participate as of mid-2026. Coverage continues to expand, but several high-population states have historically been slower to join; confirm current membership at the IMLC Commission's official registry before relying on it for a specific patient state.
• What it is not: The IMLC is not a single national license and does not supersede state licensure requirements. Each state license granted through the IMLC is still an individual state license subject to that state's rules, renewals, and disciplinary authority.
• Speed advantage: Expedited processing typically runs weeks rather than months, which makes it practical for building a network of licensed physicians across many states without multi-year timelines.
• Eligibility requirements: Physicians must meet criteria including board certification (or passing scores within defined windows), no current investigation or board action, and a principal license in an IMLC member state.

For businesses partnering with a physician-owned PC, the IMLC is the primary tool for expanding multi-state coverage efficiently. A physician in the network can be licensed in 10, 20, or more states through the compact — which is precisely why a curated national physician network is the backbone of any serious multi-state telehealth program.

Telehealth registration exceptions and patchwork state rules

Outside the IMLC, some states offer narrow telehealth-specific registration pathways that allow an out-of-state physician to conduct a limited number of consultations with in-state patients without a full state license. These are not uniform and vary significantly in scope, duration limits, permissible services, and annual encounter caps.

What these exceptions typically do and do not cover

Telehealth registration exceptions commonly apply to a consulting physician offering an opinion to an in-state treating physician — not to a physician independently evaluating and treating de novo patients for wellness or aesthetics programs. A med spa or weight-loss clinic routing patients to an out-of-state physician for standalone prescriptions generally does not fit a consulting-physician exception.

State boards have clarified in guidance and enforcement actions that these exceptions are narrow. If your business model involves a physician evaluating patients for Rx programs in states where that physician is not fully licensed, telehealth registration exceptions are unlikely to be a reliable compliance path. Full state licensure — either directly or through the IMLC — is the only defensible approach at scale.

"Telehealth eliminates the geography of the waiting room. It does not eliminate the geography of the medical license."

Controlled substances: the 2024 DEA rules and what changed after COVID

Controlled-substance prescribing via telehealth has its own federal overlay under the Controlled Substances Act and the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. Understanding the post-COVID regulatory reset is essential before building any program that involves Schedules II–V medications.

The Ryan Haight baseline

Before COVID, the Ryan Haight Act generally required an in-person medical evaluation before a practitioner could prescribe a controlled substance to a patient for the first time. This applied regardless of the technology used for subsequent care.

COVID-19 PHE flexibilities — and their end

During the COVID-19 public health emergency, DEA issued blanket exceptions permitting controlled-substance prescribing via audio-video telehealth without a prior in-person visit. These flexibilities were not permanent. When the PHE ended and the extension periods ran out, DEA promulgated final rules in 2024 establishing a permanent post-PHE telemedicine prescribing framework.

The 2024 DEA final rules: what is permitted in 2026

Under the final framework:

• Schedule III–V non-narcotic substances and buprenorphine for OUD: A DEA-registered practitioner may prescribe via a real-time audio-video telemedicine encounter without a prior in-person visit, provided a valid prescriber-patient relationship is established during that encounter. The practitioner must conduct a good-faith evaluation appropriate to the medication being prescribed.
• Schedule II substances (stimulants, most opioids, certain others): Prescribing these via telemedicine without any prior in-person visit remains significantly restricted. The rules permit very narrow exceptions — including for patients of VA providers and for prescription of Schedule II medications by certain specialty practitioners under limited conditions. For most commercial telehealth programs, prescribing Schedule II controlled substances to a new patient without an in-person evaluation is not permissible under the 2024 final rules.
• State law may be more restrictive: DEA rules set a federal floor. States may impose stricter requirements, such as prohibiting any Schedule II telehealth prescribing without in-person evaluation regardless of federal exceptions. Always confirm state-specific controlled-substance prescribing rules.
• Platform and pharmacy obligations: DEA has proposed and finalized registration requirements for telehealth platforms handling controlled-substance prescriptions. Pharmacies dispensing prescriptions written via telehealth have independent verification obligations.

Before building any telehealth Rx program, review the good-faith exam requirements that apply to every prescribing encounter, controlled or not. The exam standard and documentation requirements are distinct from — and in addition to — the DEA licensure and scheduling rules described above.

How a nationwide physician network solves multi-state coverage

The compliance math is straightforward: if you serve patients in 15 states, you need physicians licensed in each of those 15 states. Assembling that network in-house — recruiting, credentialing, negotiating, and managing individual physician contractors — is a substantial operational undertaking that most wellness and aesthetics businesses are not built to handle.

The PC-MSO model at scale

Under a compliant PC-MSO structure, the physician-owned professional corporation is the legal entity that provides all clinical services, including telehealth prescribing. The MSO provides management services — technology, scheduling, billing administration, compliance infrastructure — under a flat fair-market-value management services agreement. The MSO does not direct clinical decisions, does not employ the prescribing physicians, and does not receive compensation tied to prescription volume or revenue per script. Those arrangements implicate anti-kickback and fee-splitting rules and are not how compliant programs are structured.

When the PC is part of a pre-built national physician network, the business partner gains immediate access to licensed prescribers across the footprint without building the network from zero. The physicians remain independently licensed and clinically autonomous; the MSO handles the administrative infrastructure that makes multi-state operations operationally sustainable.

What to look for in a network partner

• Verified licensure by state: Confirm active, unrestricted licenses in each state where your patients are located — not just applications in process.
• DEA registration: Any physician prescribing controlled substances must hold a DEA registration that covers the applicable state(s). Some states require a separate state controlled-substance registration in addition to DEA registration.
• Credentialing and background checks: Physicians in the network should be credentialed to a defined standard, with no undisclosed board actions or DEA sanctions.
• Clinical independence: The network structure must preserve physician clinical authority. If the arrangement pays physicians on a per-prescription or per-patient-revenue basis, or subjects prescribing decisions to business-side approval, it creates corporate practice of medicine and potentially kickback exposure.
• Documented MSO agreement: The management services agreement should specify flat FMV compensation, define the scope of services (administrative only), and explicitly exclude the MSO from any clinical authority.

If you're expanding into new states or adding Rx services to an existing wellness or aesthetics business, the fastest path to compliant multi-state coverage is to speak with a team that already operates the licensed infrastructure — rather than building it from the ground up while patients and revenue wait. And if your program touches security-sensitive data like patient records and prescriptions, review the security and compliance standards that any technology platform handling that data should meet.